Diamonds and Dogs
Mylan (MYL) is whistling by the graveyard. The EpiPen maker, Mylan rose 8% after the company announced last Friday that it had reached a $465 million settlement with the Department of Justice about the classification of EpiPen in the Medicaid Drug Rebate Program. The DOJ settlement removes a significant overhang that had been weighing on the stock, said the analyst at RBC Capital Markets. The settlement removes any lingering concerns of a larger cash call and ongoing negative headlines, however the settlement won't end the heat Mylan continues to face from lawmakers, patients and patients families from the six-fold increase in EpiPen prices since 2007.
Dover (DOV) dove lower. The oil and gas equipment maker, Dover dropped 5% to a four month low after cutting full-year sales and profit forecasts. The company is blaming the weakness on the oil and gas markets, and a global economy that is expected to remain sluggish, adding to similar warnings from industrials like Honeywell (HON) and PPG Industries (PPG). The company slashed full-year earnings per share forecast to $3.00-$3.05 from an earlier outlook for $3.35-$3.45. Dover also now sees full-year revenue down 4% to 5%, compared to earlier guidance for a 3%-5% decline.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.